Elevated Insights

// Jul 2026

Rapid Release Testing Starts With Faster Contaminant Detection

By: Gary Sommerville Ph.D., Principal Scientist, NGS, Technical Services

View Insight

// Jul 2026

The Next Base Editors Will Be Engineered, Not Found

By, Matt Nethery, Principal Data Scientist, Computational Biology

View Insight

// Jul 2026

What Makes a Base Editor Potent and Specific Enough for Therapeutic SNP Correction?

By, Sean Crosson, Senior Scientist, Translational Biology

View Insight

// Jul 2026

Scaling Advanced Therapies and U.S. Biomanufacturing

View Insight

// Jun 2026

From Nature-Limited to AI-Designed: The Future of Gene Editing

By, Amy Pooler, Chief Scientific Officer and Matt Nethery, Principal Data Scientist, Computational Biology

View Insight

// Feb 2026

From Innovation to Impact: Building on Pittsburgh’s Legacy to Industrialize Advanced Therapies

Katie Shannon, VP, Site Head, BaseCamp Pittsburgh

View Insight

// Feb 2026

10 Questions to Ask When Choosing a Cell Therapy CDMO

Mike Paglia, Chief Technology Officer

View Insight

// Feb 2026

Why FDA Complete Response Letters Involve Manufacturing Issues – and What Must Change in Cell Therapy

By Cindy Riggins, Head of CMC Regulatory Affairs, ElevateBio

View Insight

// Nov 2025

Scaling Cell and Gene Therapies: Crossing the Inflection Point

By Mike Paglia, Chief Technology Officer, ElevateBio

View Insight

// May 2025

LETI-101: Life Edit’s Novel Gene Editing Approach to Huntington’s Disease Treatment

By Amy Pooler, Ph.D., SVP, Research and Development of Life Edit

View Insight

// Apr 2025

ElevateBio’s Next-Generation Sequencing Core: Meeting the Challenges of Cost, Time and Data Quality with Expertise and Collaboration

By Adriana Geldart, Ph.D., Senior Director, Next-Generation Sequencing, ElevateBio

View Insight

// Apr 2025

Partner Case Study: Accelerating Gene Editing Manufacturing

By ElevateBio and Beam Therapeutics

View Insight